Altuviiio logo

Menu

expand_more

HCP resources


Resources and tools for your practice

icon_dosing_guide.png

Dosing Guide
 

icon_financial_plan.png

Financial Flashcard
 

ALTUVIIIO billing and coding information

The following ICD-10-CM code may be used to identify patient medical conditions typically associated with
hemophilia A.

The following miscellenous HCPCS codes can be used for ALTUVIIIO. The prescriber is advised to verify with the payer or Medicare fiscal intermediary to determine the correct code(s).

Code typeCode numberDescription
ICD-10-CMD66Hereditary Factor VIII deficiency
HCPCSJ7214Injection, Factor VIII/von Willebrand factor complex, recombinant (ALTUVIIIO) per Factor VIII IU
C9399Unclassified drugs or biologics (Medicare hospital outpatient setting)

 

ALTUVIIIO National Drug Codes (NDCs)

NDCs are unique 3-segment numbers that serve as universal product identifiers for human drugs in the US.1 The bolded "0" in the NDC column below represents the 11th digit required for filing claims. Payer requirements for NDC use and format may vary. Please contact each payer for specific coding policies.

Strength2NDC2
250 IU71104-0978-01
500 IU71104-0979-01
1000 IU71104-0981-01
2000 IU71104-0982-01
3000 IU71104-0983-01
4000 IU71104-0984-01

This billing and coding information is provided for informational purposes only and does not constitute legal or reimbursement advice. It is not intended to substitute for the physician’s independent diagnosis or treatment of each patient. The information contained herein is gathered from various resources and is subject to change. Providers are solely responsible for the accuracy of all coding and claims submitted for reimbursement to any third-party payer.

img_labcorp.png

Free laboratory tests for ALTUVIIIO

Sanofi has contracted with LabCorp (Esoterix) to provide a central lab to perform standardized one-stage clotting assays with a national network of local laboratories for specimen collection at no extra cost for the patient or healthcare provider.

Learn more information about monitoring with LabCorp.

icon_Simple-Dosing.png

Simple dosing with ALTUVIIIO

Infused the same way as Factor VIII replacement therapies but taken less frequently.

icon_bubble.png

Resources for your patients

ALTUVIIIO offers a range of helpful resources and access programs for your patients.

Indication

ALTUVIIIO® [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a von Willebrand Factor (VWF) independent recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for:

  • Routine prophylaxis to reduce the frequency of bleeding episodes
  • On-demand treatment & control of bleeding episodes
  • Perioperative management of bleeding
Limitation of Use

ALTUVIIIO is not indicated for the treatment of von Willebrand disease.

Important Safety Information
Contraindications

ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients.

Warnings and Precautions
  • Allergic-type hypersensitivity reactions, including anaphylaxis, may occur with ALTUVIIIO. Allergic-type hypersensitivity reactions were not reported in the clinical trials. Advise patients to discontinue use of ALTUVIIIO if hypersensitivity symptoms occur and contact a physician and/or seek immediate emergency care.
  • Formation of neutralizing antibodies (inhibitors) to Factor VIII are possible following administration of ALTUVIIIO. Neutralizing antibodies were not reported in the clinical trials. Monitor all patients for the development of Factor VIII inhibitors by appropriate clinical observations and laboratory tests.
  • If assessment of plasma Factor VIII activity is needed, it is recommended to use a validated one-stage clotting assay. The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid-based aPTT reagent in one-stage clotting assay by approximately 2.5-fold. If these assays are used, divide the result by 2.5 to approximate the patient's ALTUVIIIO Factor VIII activity level.
Adverse Reactions

The most common adverse reactions (>10% of subjects) reported in clinical trials were headache and arthralgia.

IndicationImportant Safety Information

HCPCS=Healthcare Common Procedure Coding System; IU=international unit.

Reference: 1. US Food and Drug Administration. National Drug Code Directory. Updated July 22, 2022. Accessed September 8, 2023. https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory 2. ALTUVIIIO Prescribing Information. Bioverativ Therapeutics Inc. Waltham, MA.

© 2024 Sanofi. All rights reserved. ALTUVIIIO, MyALTUVIIIO, and Sanofi are registered trademarks of Sanofi or an affiliate.

MAT-US-2403562-v1.0-05/2024 Last Updated: May 2024